AA
BIO icon

ALPS Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

ALPS Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-630
Closed -$312K – 1069
2022
Q2 		$312K Sell
630
-7
-1% -$3.65K ﹤0.01% 770
2022
Q1 		$359K Buy
637
+175
+38% +$105K ﹤0.01% 618
2021
Q4 		$349K Buy
462
+10
+2% +$7.48K ﹤0.01% 779
2021
Q3 		$337K Sell
452
-152
-25% -$114K ﹤0.01% 811
2021
Q2 		$389K Hold
604
– – ﹤0.01% 590
2021
Q1 		$345K Buy
604
+95
+19% +$56.3K ﹤0.01% 609
2020
Q4 		$297K Sell
509
-10
-2% -$5.7K ﹤0.01% 717
2020
Q3 		$268K Sell
519
-40
-7% -$20.3K ﹤0.01% 640
2020
Q2 		$252K Sell
559
-60
-10% -$26.5K ﹤0.01% 640
2020
Q1 		$217K Sell
619
-417
-40% -$153K ﹤0.01% 720
2019
Q4 		$383K Sell
1,036
-45
-4% -$15.9K ﹤0.01% 610
2019
Q3 		$360K Buy
+1,081
New +$353K ﹤0.01% 634

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ALPS Advisors's BIO Position: Q3 2022 in Review

ALPS Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 630 shares — an estimated $312K sold.

ALPS Advisors first reported a position in BIO in Q3 2019 and held it in 12 quarters. The position peaked at $389K in Q2 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • ALPS Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • ALPS Advisors sold 630 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $312K.
  • ALPS Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 12 quarters.
  • ALPS Advisors's Bio-Rad Laboratories Class A position peaked at $389K in Q2 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on ALPS Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.